Comprehensive Financial Planning Inc. PA Buys New Position in Bristol-Myers Squibb (NYSE:BMY)

Comprehensive Financial Planning Inc. PA purchased a new position in shares of Bristol-Myers Squibb (NYSE:BMY) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 608 shares of the biopharmaceutical company’s stock, valued at approximately $34,000.

Other hedge funds have also recently added to or reduced their stakes in the company. AMF Tjanstepension AB grew its holdings in Bristol-Myers Squibb by 6.9% in the third quarter. AMF Tjanstepension AB now owns 610,181 shares of the biopharmaceutical company’s stock valued at $31,618,000 after purchasing an additional 39,419 shares during the period. Ritholtz Wealth Management lifted its position in Bristol-Myers Squibb by 81.0% during the third quarter. Ritholtz Wealth Management now owns 23,843 shares of the biopharmaceutical company’s stock valued at $1,234,000 after buying an additional 10,669 shares in the last quarter. Exchange Traded Concepts LLC increased its position in shares of Bristol-Myers Squibb by 18.1% in the third quarter. Exchange Traded Concepts LLC now owns 26,468 shares of the biopharmaceutical company’s stock worth $1,369,000 after acquiring an additional 4,064 shares in the last quarter. Koshinski Asset Management Inc. lifted its holdings in shares of Bristol-Myers Squibb by 3.5% during the 3rd quarter. Koshinski Asset Management Inc. now owns 26,568 shares of the biopharmaceutical company’s stock valued at $1,375,000 after acquiring an additional 904 shares in the last quarter. Finally, Sound Income Strategies LLC increased its holdings in Bristol-Myers Squibb by 46.9% in the 3rd quarter. Sound Income Strategies LLC now owns 2,770 shares of the biopharmaceutical company’s stock valued at $143,000 after purchasing an additional 885 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Price Performance

BMY stock opened at $55.50 on Tuesday. The firm has a 50-day moving average of $57.56 and a two-hundred day moving average of $53.89. The firm has a market capitalization of $112.55 billion, a PE ratio of -12.56, a P/E/G ratio of 2.13 and a beta of 0.45. The company has a current ratio of 1.24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $61.10.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.81% and a negative net margin of 18.53%. On average, analysts forecast that Bristol-Myers Squibb will post 6.75 earnings per share for the current year.

Bristol-Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd were paid a $0.62 dividend. The ex-dividend date of this dividend was Friday, January 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 4.47%. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s payout ratio is -56.11%.

Analyst Ratings Changes

A number of research analysts have recently commented on BMY shares. Cantor Fitzgerald boosted their target price on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Leerink Partners raised shares of Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $55.00 to $73.00 in a research report on Tuesday, November 12th. Daiwa America upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 13th. Daiwa Capital Markets raised shares of Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a report on Wednesday, November 13th. Finally, Wolfe Research began coverage on Bristol-Myers Squibb in a research note on Friday, November 15th. They issued a “peer perform” rating for the company. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $57.86.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.